Okay, let's tackle this question about Levonorgestrel IUS and its benefits in treating AUB. The question is asking which benefit is NOT provided by the Levonorgestrel IUS. First, I need to recall what AUB stands for—abnormal uterine bleeding. The Levonorgestrel intrauterine system (LNG-IUS) is a hormonal contraceptive that releases levonorgestrel directly into the uterus.

The core concept here is understanding the pharmacological and physiological effects of LNG-IUS. It's a progestin-only method, so it works by thickening cervical mucus, inhibiting endometrial proliferation, and suppressing ovulation in some cases. The main benefits include reducing menstrual bleeding, often leading to amenorrhea, and treating conditions like heavy menstrual bleeding.

Now, the correct answer is the option that's not a benefit. Common benefits of LNG-IUS include reduced menstrual flow, treatment of AUB, management of endometriosis, and prevention of pregnancy. However, it does not protect against sexually transmitted infections (STIs). So if one of the options states that it provides STI protection, that would be the exception.

Looking at the options, if an option mentions STI protection, that's the incorrect benefit. Other possible incorrect options might be things like weight loss or acne improvement, which aren't associated with LNG-IUS. Alternatively, maybe an option about promoting fertility, but LNG-IUS is a contraceptive, so that would be wrong too. However, the key here is the exception in the context of AUB treatment. Since the question is about AUB, the main benefits are related to bleeding control. The most common exception is STI protection. So the correct answer is the option that claims it provides STI protection.

**Core Concept**
Levonorgestrel intrauterine system (LNG-IUS) is a progestin-only contraceptive indicated for treating abnormal uterine bleeding (AUB). It reduces endometrial proliferation and bleeding via localized progestin effects, but does not confer non-contraceptive benefits like STI protection.

**Why the Correct Answer is Right**
LNG-IUS **does not protect against sexually transmitted infections (STIs)**. Its mechanism involves endometrial thinning, suppression of ovulation (in some cases), and cervical mucus thickening, which reduce menstrual bleeding and pregnancy risk. However, it lacks physical or biochemical barriers against pathogens, unlike condoms. This absence of STI protection is a critical clinical limitation.

**Why Each Wrong Option is Incorrect**
**Option A:** *Reduces menstrual blood loss* – Correct benefit; LNG-IUS is FDA-approved for heavy menstrual bleeding.
**Option B:** *May induce amenorrhea* – Correct benefit; 20–30% of users achieve amenorrhea within 12 months.
**Option C:** *Reduces risk of endometrial hyperplasia* – Correct benefit; progestins prevent endometrial proliferation.

**Clinical Pearl / High-Yield Fact**
LNG-IUS is first-line for AUB due to its efficacy in reducing bleeding and endometrial risks. **Never assume it prevents STIs**—this is a common exam trap. Always advise concurrent condom use for STI prevention.

**Correct Answer: D. Provides protection against sexually transmitted infections**

✓ Correct Answer: C. No break-through bleeding